| Background And Objective:Bronchial asthma(hereinafter referred to as asthma)is a common chronic airway disease,although most asthma patients respond well to inhaled corticosteroids(ICS)/Long-term effect β Bronchodilator(LABA)treatment,but patients with severe asthma have limited benefits from ICS/LABA treatment.Omalizumab is the first anti-IgE monoclonal antibody used to treat severe asthma,which can reduce the acute attack rate of severe asthma and improve the quality of life.However,there is a lack of effective serum biomarkers to evaluate the efficacy of omalizumab in the treatment of severe asthma and the indication of discontinuation.This study aims to explore the clinical significance of Hsp90α、IL-1βand IFN-β in patients with severe asthma.Methods:This study included 33 asthma patients(13 non-severe asthma patients,10 severe asthma patients who were not treated with omazulimab,and 10 severe asthma patients who had been treated with omalizumab)and 19 healthy controls.Separate the peripheral serum samples of asthma patients and healthy control group,and detect the level of Hsp90α、IFN-β and IL-1β in serum by ELISA detection method.Analyze the clinical characteristics and the level of serum Hsp90α、IL-1β、IFN-β in each group through SPSS 24.0 software whether there are statistical differences.Results:Our results showed that:(1)the level of Hsp90α in peripheral serum of asthmatic patients(83.39 ± 28.77 pg/mL,p=0.003<0.05)was conspicuously higher than that of healthy control group(57.33±23.18 pg/mL),the level of IL-1β(8.20±2.53pg/mL,p=0.889>0.05)and IFN-β(59.83±23.53pg/mL,p=0.743>0.05)in serum were slightly higher than that of the healthy control group(7.95±2.45pg/mL,55.71±12.91pg/mL),but it did not reach statistical significance.(2)The level of IL-1β in peripheral serum of patients with severe asthma(9.59±2.60 pg/mL,p=0.013<0.05)was conspicuously higher than that of non-severe asthma patients(7.13±1.94 pg/mL).(3)The level of Hsp90α(100.98±9.75pg/mL,p=0.007<0.05)and IFN-β(74.14±11.11 pg/mL,p=0.022<0.05)in peripheral serum of patients with asthma during acute attack were conspicuously higher than that of the stable asthma group(54.32±7.40 pg/mL,43.20±7.67 pg/mL).(4)The level of Hsp90α(93.91±11.01 pg/mL,p=0.028<0.05)in the peripheral serum of the uncontrolled asthma group was sensibly higher than that of the controlled asthma group(56.30±8.73 pg/mL).(5)The level of Hsp90α(64.28±13.63 pg/mL,p=0.007<0.05)and IL-1β(7.51±1.33 pg/mL,p=0.026<0.05)in the peripheral blood of patients with severe asthma who have been treated with omalizumab was sensibly lower than that of patients with severe asthma who were not treated with omalizumab(88.51±23.76 pg/mL,9.59±2.60 pg/mL).Conclusions:(1)The level of Hsp90α in peripheral serum of asthmatic patients was sensibly higher than that of healthy people.(2)Peripheral serum IL-1β level in severe asthma was sensibly higher than that of non-severe asthma.(3)The level of serum Hsp90α and IFN-β in patients with acute attack phase of asthma was sensibly higher than that in patients with stable phase of asthma.(4)The peripheral serum Hsp90α in the uncontrolled asthma group was sensibly higher than that in the control asthma group.(5)The level of Hsp90α and IL-1β in peripheral serum of patients with severe asthma treated with omalizumab were sensibly lower than that of patients with severe asthma who did not receive omalizumab treatment.Serum Hsp90α,IL-1β and IFN-β may be biomarkers of asthma,especially Hsp90α and IL-1β may play an important role in severe asthma and its clinical treatment. |
PDF Full Text Request